The Proton Pump Inhibitors (PPIs) was introduced to the market in 1989 which advanced the medical treatment of acid-related disorders. Acid-related disorders is used to describe a spectrum of conditions in which acid is involved in the generation of symptoms and / or complications.
They are amongst the most usually prescribed agents in inpatient and outpatient settings. It is positioned as the sixth most frequently dispensed therapeutic class in the US and third in Ireland in 2009. As per the IMS Health,PPIs were the ninth most regularly prescribed drugs in 2015.
Proton-pump inhibitors are a group of drugs, whose fundamental activity is long-lasting reduction of gastric acid production by irreversibly inhibiting the gastric H+K+ATPase.
Several …show more content…
Studies conducted on secondary care found that around 68% Italy, 65% US, 63% Australia, 51% UK ,40% New Zealand, and 33% Ireland did not have appropriate indication for their PPI …show more content…
Vitamin B12 malabsorption is another issue associated with PPI therapy. Thus,it is reasonable to assess vitamin B12 levels periodically (eg.annually) in patients who are on long-term treatment.
Another problem associated with PPI use is enteric infections.The risk of enteric infections associated with PPI utilization fixates on the hypothesis of as pH rises above 4, there is impaired destruction of ingested microorganisms by gastric acid.
Several studies have observed hospital-acquired CDAD(Clostridium difficile-associated diarrrhoea) with PPI usage. A case-controlled study discovered a 2.5 fold risk of CDAD in 170 hospitalized patients in the UK with PPI therapy and a greater than 5-fold risk is associated with both PPI and antibiotics use.
In conclusion,inappropriate recommendation of PPIs is a matter of concern. Patients with no clinical indication for usage are only exposed to the risks of prescribed
They are amongst the most usually prescribed agents in inpatient and outpatient settings. It is positioned as the sixth most frequently dispensed therapeutic class in the US and third in Ireland in 2009. As per the IMS Health,PPIs were the ninth most regularly prescribed drugs in 2015.
Proton-pump inhibitors are a group of drugs, whose fundamental activity is long-lasting reduction of gastric acid production by irreversibly inhibiting the gastric H+K+ATPase.
Several …show more content…
Studies conducted on secondary care found that around 68% Italy, 65% US, 63% Australia, 51% UK ,40% New Zealand, and 33% Ireland did not have appropriate indication for their PPI …show more content…
Vitamin B12 malabsorption is another issue associated with PPI therapy. Thus,it is reasonable to assess vitamin B12 levels periodically (eg.annually) in patients who are on long-term treatment.
Another problem associated with PPI use is enteric infections.The risk of enteric infections associated with PPI utilization fixates on the hypothesis of as pH rises above 4, there is impaired destruction of ingested microorganisms by gastric acid.
Several studies have observed hospital-acquired CDAD(Clostridium difficile-associated diarrrhoea) with PPI usage. A case-controlled study discovered a 2.5 fold risk of CDAD in 170 hospitalized patients in the UK with PPI therapy and a greater than 5-fold risk is associated with both PPI and antibiotics use.
In conclusion,inappropriate recommendation of PPIs is a matter of concern. Patients with no clinical indication for usage are only exposed to the risks of prescribed